Brief: Biogen And Stoke Therapeutics Enter Into Collaboration

Stoke Therapeutics

18/02/2025 15:00

Feb 18 (Reuters) - Biogen Inc  BIIB.O :
    * BIOGEN AND STOKE THERAPEUTICS ENTER INTO COLLABORATION TO
DEVELOP AND COMMERCIALIZE ZOREVUNERSEN FOR THE TREATMENT OF
DRAVET SYNDROME, A RARE GENETIC EPILEPSY ASSOCIATED WITH
REFRACTORY SEIZURES AND NEURODEVELOPMENTAL IMPAIRMENTS
    * BIOGEN INC - PHASE 3 STUDY OF ZOREVUNERSEN TO INITIATE IN
Q2
2025
    * BIOGEN INC - STOKE RETAINS EXCLUSIVE RIGHTS FOR
ZOREVUNERSEN IN
US, CANADA, MEXICO; BIOGEN GETS REST OF WORLD

Source text:  ID:nBwbh3DmPa 
Further company coverage:  BIIB.O 

 ((reuters.briefs@thomsonreuters.com;))